Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement

Rituximab (RTX) is non-inferior to cyclophosphamide (CYC) followed by azathioprine (AZA) for remission-induction in severe ANCA-associated vasculitis (AAV), but renal outcomes are unknown. This is a post hoc analysis of patients enrolled in the Rituximab for ANCA-Associated Vasculitis (RAVE) Trial w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Soc Nephrol
Main Authors: Geetha, Duvuru, Specks, Ulrich, Stone, John H., Merkel, Peter A., Seo, Philip, Spiera, Robert, Langford, Carol A., Hoffman, Gary S., Kallenberg, Cees G.M., St. Clair, E. William, Fessler, Barri J., Ding, Linna, Tchao, Nadia K., Ikle, David, Jepson, Brett, Brunetta, Paul, Fervenza, Fernando C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2015
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4378104/
https://ncbi.nlm.nih.gov/pubmed/25381429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2014010046
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados